newcastl
diseas
viru
ndv
one
five
speci
virus
clinic
evalu
vector
oncolyt
cancer
therapi
gene
therapi
immun
stimul
concept
use
virus
treat
human
cancer
date
back
earli
rational
receiv
support
welldocu
remiss
malign
induc
natur
viral
infect
measl
mump
upon
vaccin
attenu
viral
vaccin
observ
stimul
transient
peak
research
activ
receiv
new
interest
basi
new
preclin
clinic
result
among
virus
use
rna
virus
rapidli
emerg
particularli
promis
agent
viru
therapi
cancer
integr
live
cycl
rna
virus
format
doublestrand
rna
dsrna
activ
spectrum
cellular
defenc
mechan
involv
type
interferon
interferon
ifn
tumor
provid
rel
permiss
substrat
propag
rna
virus
mutat
tumor
cell
often
crippl
interferon
system
allow
uninhibit
prolifer
provid
resist
apoptosi
promis
rna
virus
attenu
strain
mump
viru
ndv
measl
viru
vesicular
stomat
viru
human
reoviru
polioviru
influenza
viru
although
human
rna
virus
abil
evolut
adapt
human
immun
system
develop
immun
escap
mechan
advantag
ndv
bird
viru
adapt
avian
immun
system
viru
name
come
site
first
report
diseas
outbreak
among
chicken
farm
near
newcastleupontyn
england
ndv
classifi
avian
paramyxoviru
apmv
rubulaviru
genu
famili
paramyxovirida
order
mononegavirali
ndv
envelop
viru
diamet
negativesens
singlestrand
rna
genom
roughli
nucleotid
code
six
gene
encod
six
major
polypeptid
larg
protein
l
kda
protein
hn
kda
fusion
protein
f
kda
matrix
protein
kda
phosphoprotein
p
kda
nucleoprotein
np
kda
mean
overlap
read
frame
p
gene
encod
addit
gene
product
v
protein
rnadepend
rna
polymeras
involv
protein
l
p
np
translat
infect
cell
free
ribosom
cytoplasm
f
glycoprotein
synthes
inact
precursor
kda
undergo
proteolyt
cleavag
yield
biolog
activ
protein
consist
disulfidelink
chain
kda
kda
detail
classif
structur
ndv
see
ref
first
hint
potenti
anticanc
benefit
viru
patient
made
year
ago
wheelock
dingl
report
signific
reduct
leukem
blast
patient
myelogen
leukemia
treat
intraven
iv
administr
ndv
cassel
garrett
report
effect
intratumor
ndv
treatment
patient
cervic
cancer
mark
tumor
shrinkag
inject
mass
well
supraclavicular
lymph
node
metastasi
observ
patient
toler
treatment
well
csatari
note
chicken
farmer
shortli
known
exposur
ndv
flock
infect
chicken
spontan
remiss
metastat
cancer
report
note
tumor
regress
three
patient
intent
inocul
ndv
sinc
time
certain
number
clinic
studi
use
viru
cancer
therapi
perform
ndv
label
complementari
altern
medicin
cam
nation
cancer
institut
nci
usa
detail
inform
found
home
page
nci
sinc
first
observ
show
antineoplast
properti
ndv
differ
concept
investig
process
develop
regard
use
ndv
cancer
treatment
vaccin
purpos
use
tumor
select
cytolysi
viral
oncolysi
use
nonspecif
immun
stimul
induct
cytokin
interferon
use
adjuv
danger
signal
ds
tumor
vaccin
stimul
cytotox
lymphocyt
ctl
delayedtyp
hypersensit
dth
respons
use
viral
vector
transfer
therapeut
gene
use
vaccin
vector
immun
emerg
pathogen
infect
cell
ndv
schemat
divid
two
step
illustr
fig
first
step
involv
bind
viru
host
cell
surfac
via
cellbind
domain
hn
molecul
follow
activ
fusion
protein
f
concert
action
hn
f
lead
fusion
viral
host
cell
membran
membran
fusion
event
allow
viral
genom
enter
cytoplasm
host
cell
negativestrand
rna
genom
transcrib
messeng
rna
mrna
translat
viral
protein
first
step
protein
np
p
l
requir
nucleocapsid
assembl
nucleocapsid
antigenom
use
templat
viral
replic
second
step
protein
envelop
protein
hn
f
posttransl
modif
move
membran
viru
assembl
bud
occur
process
singl
copi
ndv
genom
becom
wrap
outer
coat
envelop
made
host
cell
plasma
membran
effici
replic
observ
depend
genom
length
multipl
six
requir
known
rule
six
assum
np
subunit
contact
exactli
six
nucleotid
arrang
requir
effici
replic
represent
may
simplist
shown
recent
envelop
virus
ndv
enter
cell
two
main
pathway
via
direct
fusion
envelop
plasma
membran
describ
ndv
establish
membran
fusion
process
take
place
host
plasma
membran
phindepend
manner
activ
fusion
protein
f
occur
interact
viral
glycoprotein
sialic
acidcontain
cellular
receptor
gangliosid
nglycoprotein
ubiquit
express
cell
surfac
ii
via
receptormedi
endocytosi
recent
shown
ndv
might
also
infect
cell
caveolaedepend
endocyt
pathway
altern
rout
certain
percentag
virion
might
endocytos
endosom
fusion
would
occur
lower
ph
order
assembl
releas
infecti
ndv
particl
shown
depend
membran
lipid
raft
defin
cholesterol
sphingolipidrich
microdomain
exoplasm
leaflet
cellular
plasma
membran
newli
produc
virion
show
accumul
hn
f
np
viral
protein
lipid
raft
earli
synthesi
contain
lipid
raftassoci
protein
actin
nonlipid
raftassoci
transfer
receptor
assembl
releas
ndv
viruslik
particl
vlp
avian
cell
express
possibl
combin
viral
protein
reveal
protein
necessari
suffici
vlp
mhn
mnp
interact
respons
incorpor
vlp
f
protein
incorpor
due
interact
np
hn
protein
although
nontumorigen
human
cell
even
activ
cultur
interleukin
il
replic
cycl
ndv
stop
tumor
cell
continu
replic
cycl
produc
viral
particl
within
h
infect
see
fig
certain
ndv
strain
replic
time
better
human
neoplast
transform
cell
normal
human
cell
appear
basi
wide
accept
fact
viru
virtual
nontox
human
interest
use
form
cancer
therapi
remark
strong
capac
ndv
induc
type
interferon
respons
viral
protein
rna
fig
viral
rna
replic
induc
infect
cell
innat
antivir
program
initi
transcript
rnarespons
gene
respons
involv
multimod
machineri
gene
regul
interferon
regulatori
factor
irf
famili
transcript
factor
ndv
stimul
human
peripher
blood
mononuclear
cell
pbmc
interferoninduc
gene
isg
antivir
enzym
protein
kinas
r
pkr
dsrnarespons
protein
kinas
mxa
dynaminlik
gtpase
antivir
activ
rnasel
latter
recent
shown
gener
small
selfrna
therebi
amplifi
antivir
innat
immun
clarifi
underli
mechan
observ
differ
viru
suscept
infect
tumor
cell
nontumor
cell
examin
kinet
interferoninduc
antivir
enzym
analysi
reveal
sever
defect
tumor
cell
antivir
defenc
respons
show
respons
uvinactiv
ndv
wherea
nontumorigen
cell
react
induct
high
level
antivir
enzym
pkr
mxa
conclud
induct
earli
effici
antivir
respons
nontumorigen
cell
could
explain
stop
replic
cycl
ndv
product
positivestrand
rna
contrast
tumor
cell
show
weak
delay
antivir
respons
see
fig
observ
may
explain
continu
replic
cycl
lead
high
express
viral
protein
ndv
strain
suitabl
antineoplast
therapi
classifi
either
lytic
nonlyt
human
cell
fig
lytic
strain
nonlyt
strain
replic
much
effici
human
neoplast
cell
normal
human
cell
virus
strain
type
investig
potenti
anticanc
agent
one
major
differ
lytic
nonlyt
strain
lytic
strain
abl
make
infecti
progeni
viru
particl
human
neoplast
cell
wherea
nonlyt
strain
reason
progeni
viru
particl
made
nonlyt
strain
contain
inact
version
f
molecul
advantag
lytic
properti
ndv
strain
product
infecti
progeni
viru
particl
first
round
viral
infect
give
abil
spread
viru
tumor
tissu
via
multicycl
replic
see
fig
right
contrast
nonlyt
strain
perform
monocycl
replic
cycl
see
fig
left
oncolyt
ndv
strain
cytotox
human
tumor
cell
line
ectoderm
endoderm
mesoderm
origin
exert
oncolysi
intrins
extrins
caspasedepend
pathway
cell
death
ndv
infect
shown
result
loss
mitochondri
membran
potenti
releas
mitochondri
protein
cytochrom
c
addit
lead
earli
activ
caspas
caspas
contrast
cleavag
caspas
predominantli
activ
death
receptor
pathway
late
event
ndvmediat
apoptosi
tumor
cell
induc
tumor
necrosi
factor
tnf
relat
apoptosisinduc
ligand
trail
death
signal
gener
ndv
tumor
cell
ultim
converg
mitochondria
recent
studi
reveal
human
glioblastoma
cell
line
repress
express
protein
show
differ
ndv
sensit
cell
indic
apoptot
process
induc
ndv
depend
two
human
tumor
cell
line
viru
replic
led
sign
endoplasm
reticulum
stress
phosphoryl
protein
kinas
r
pkr
like
endoplasm
reticulum
kinas
elong
factor
alpha
thu
vitro
oncolyt
ndv
select
kill
tumor
cell
cultur
induc
endoplasm
reticulum
stress
lead
apoptot
cell
death
cytotox
properti
rais
consider
interest
recent
year
clinic
applic
oncolyt
ndv
virus
vivo
tumoricid
activ
evalu
athym
nude
mice
subcutan
inject
tumor
cell
follow
intralesion
inject
plaqu
form
unit
pfu
oncolyt
ndv
treatment
caus
complet
tumor
regress
athym
mice
high
therapeut
index
recent
character
virolog
immunolog
antitumor
properti
ndv
strain
observ
oncolyt
strain
potent
induc
among
ndv
strain
test
ultraviolet
light
uv
inactiv
strain
one
test
could
induc
human
pbmc
antitumor
activ
vitro
upon
system
applic
high
dose
ndv
mice
bear
virussuscept
intraderm
tumor
signific
antitumor
effect
observ
two
oncolyt
strain
italien
treatment
nevertheless
signific
side
effect
seen
loss
bodi
weight
contrast
use
locoregion
applic
system
treatment
liver
metastas
luciferasetransfect
murin
colon
carcinoma
cell
show
signific
delay
tumor
growth
well
prolong
surviv
effect
bodi
weight
surprisingli
murin
tumor
cell
transfect
resist
vitro
viru
infect
oncolysi
result
suggest
locoregion
applic
oncolyt
ndv
effect
system
iv
applic
ii
oncolyt
ndv
may
mediat
effect
virusresist
tumor
line
possibl
via
hostmedi
mechan
explan
vivo
mechan
induc
oncolyt
ndv
strain
therefor
includ
hostmedi
mechan
dealt
within
follow
section
detail
human
nk
cell
activ
antitumor
cytotox
activ
ndv
infect
tumor
cell
contrast
uninfect
tumor
cell
activ
nk
cell
exert
vitro
signific
bystand
antitumor
activ
stimul
cultur
perform
top
human
tumor
cell
monolay
antivir
respons
nk
cell
involv
induct
trail
ndv
shown
also
activ
murin
macrophag
variou
macrophag
enzym
adenosin
deaminas
ada
induc
nitric
oxid
synthas
ino
lysozym
acid
phosphatas
becom
upregul
antitumor
effector
molecul
nitric
oxid
tumor
necrosi
factor
tnf
detect
supernat
ndvactiv
macrophag
perform
antitumor
cytotox
vitro
variou
tumor
line
includ
immun
escap
variant
addit
repeat
intraven
transfer
ndvactiv
macrophag
observ
exert
signific
suppress
effect
pulmonari
metastas
mammari
lung
carcinoma
fig
induct
synthesi
macrophag
ndv
associ
activ
nuclear
factorkb
nfkb
reaction
part
activ
process
includ
stimul
ada
inhibit
nucleotidas
suggest
signal
requir
nfkb
activ
product
similar
ndvactiv
macrophag
anoth
studi
trail
shown
mediat
tumoricid
activ
human
monocyt
stimul
ndv
within
h
coincub
monocyt
ndv
strong
induct
mrna
trail
observ
h
ndvactiv
monocyt
exert
antitumor
cytotox
activ
kill
receptorexpress
tumor
line
cytotox
activ
could
partial
block
solubl
trailfc
recombin
fusion
protein
inhibitor
ino
task
dc
consist
uptak
process
present
antigen
well
recognit
danger
signal
dc
produc
great
number
pbmcderiv
monocyt
modc
load
dc
antigen
done
vivo
well
vitro
dsrna
motif
describ
lead
matur
activ
protect
dc
antigen
tumor
cell
associ
danger
signal
viru
infect
use
virusinfect
tumor
cell
oncolys
dc
load
fig
dendrit
cell
puls
viral
oncolys
report
potent
stimul
autolog
cell
cancer
patient
studi
dc
breast
cancer
patient
puls
lysat
breast
cancer
line
tul
ndvinfect
cell
tunl
viral
oncolys
compar
stimulatori
capac
enzymelink
immuno
spot
techniqu
elispot
respons
autolog
bone
marrow
bm
deriv
memori
cell
dc
puls
viral
oncolys
show
increas
express
costimulatori
molecul
induc
significantli
higher
elispot
memori
cell
respons
supernat
cocultur
contain
increas
titer
interleukin
il
comparison
cocultur
cell
dc
puls
noninfect
tumor
lysat
known
drive
monocyt
differenti
toward
dc
also
import
effect
cell
prolifer
mainten
memori
cell
recent
describ
human
dc
effici
prime
melanomaspecif
naiv
cell
differenti
ctl
result
suggest
dc
prepar
puls
viral
oncolys
includ
danger
signal
eg
dsrna
cytokin
heatshock
protein
superior
cell
stimul
dc
prepar
puls
lysat
noninfect
tumor
cell
ndv
also
effect
lymphocyt
infect
murin
esb
tumor
cell
low
amount
ndv
suffici
lead
increas
cytolyt
activ
tumorspecif
ctl
sensit
vivo
restimul
vitro
number
esbspecif
ctl
per
spleen
could
rais
test
limit
dilut
analysi
splittyp
experi
could
shown
clonal
level
viral
modif
alter
specif
esbspecif
ctl
thu
ndv
modif
tumor
cell
led
select
augment
taaspecif
ctl
anoth
studi
modif
tumor
cell
low
dose
ndv
led
augment
tumorspecif
cell
respons
result
immun
cell
cooper
esbndvimmun
helper
cell
produc
antigen
stimul
correspond
esb
immun
cell
virusmedi
augment
ctl
respons
involv
increas
helper
activ
involv
recognit
viral
epitop
potenti
new
helper
determin
term
viral
xenogen
tumor
cell
thu
inappropri
describ
mechan
function
ndv
tumor
vaccin
postop
activ
tumorspecif
ctl
precursor
ctlp
mice
metastas
requir
stimul
specif
antigen
addit
signal
incorpor
analysi
immun
statu
spleen
tumorbear
tumorimmun
mice
reveal
import
differ
activ
ctlp
mice
metastas
tumorimmun
mice
requir
helper
factor
ndv
studi
also
underli
mechan
cell
stimul
detail
viral
hn
protein
ndv
shown
augment
peptidespecif
cytotox
cell
respons
greater
sixfold
increas
influenza
nucleoprotein
peptid
correspond
amino
acid
protein
specif
ctl
respons
observ
cultur
restimul
peptidepuls
syngen
ltk
fibroblast
cell
coexpress
viral
hn
protein
due
either
infect
hn
complementari
dna
cdna
transfect
find
suggest
hn
express
antigenpres
cell
tumor
cell
exert
cell
costimulatori
function
ndv
infect
human
melanoma
cell
report
mediat
cell
costimulatori
function
break
anergi
viral
oncolys
ndv
wide
use
treatment
malign
melanoma
melanoma
cell
tumorinfiltr
lymphocyt
til
prepar
freshli
resect
tumor
til
subject
limit
dilut
clone
one
helper
clone
unrespons
stimul
autolog
tumor
cell
remain
unrespons
even
subsequ
stimul
ndv
infect
melanoma
cell
complet
restor
prolif
respons
helper
cell
also
prevent
induct
anergi
electrophoret
mobil
shift
assay
reveal
induct
complex
cell
coincub
ndvinfect
melanoma
cell
furthermor
activ
pathway
involv
ligand
assay
tumor
cell
infect
ndv
show
increas
adhes
erythrocyt
lymphocyt
increas
adhes
could
block
monoclon
antibodi
mab
hn
f
hn
cdna
transfect
also
mediat
increas
lymphocyt
adhes
mutant
ndv
strain
australian
victoria
highli
decreas
neuraminidas
activ
similar
ndv
strain
ulster
adhes
cell
costimulatori
function
wherea
parent
av
strain
high
neuraminidas
activ
hn
molecul
neg
function
costimulatori
effect
ndv
ulster
virion
reveal
virion
suboptim
concentr
mab
coat
microtit
plate
induct
murin
cell
prolifer
human
autolog
mix
lymphocyt
tumor
cultur
mltc
upregul
cell
activ
marker
observ
ndv
modifi
nonmodifi
tumor
cell
anoth
explan
enhanc
antitumor
immun
respons
addit
addit
ndv
onto
tumor
cell
attribut
fact
human
tumor
cell
infect
ndv
found
lead
upregul
hla
molecul
infect
live
inact
ndv
induc
tumor
cell
test
chemokin
rant
protein
chemokin
increas
chemotaxi
lead
recruit
monocyt
cell
site
vaccin
applic
seventytwo
hour
infect
tumor
cell
live
ndv
ulster
mani
tumor
cell
dead
earli
late
stage
apoptosi
apoptosi
often
character
noninflammatori
cell
death
set
viru
infect
apoptosi
might
howev
promot
inflammatori
respons
lead
antigen
cross
prime
infect
ndv
cell
host
immun
system
induc
strong
innat
immun
respons
character
rapid
product
type
interferon
lead
inhibit
viru
replic
antivir
respons
initi
recognit
viral
product
dsrna
two
type
pathogen
recognit
receptor
tolllik
receptor
tlr
rigilik
receptor
rlr
tlr
famili
consist
ten
member
express
cell
surfac
membran
endosom
rlr
famili
cytoplasm
rna
helicas
includ
rigi
dsrna
molecul
synthes
ndv
replic
cytoplasm
recogn
cell
type
pathogen
typespecif
manner
studi
mice
reveal
convent
dendrit
cell
cdc
macrophag
fibroblast
isol
mice
impair
type
ifn
induct
infect
rna
virus
wherea
product
ifn
still
observ
plasmacytoid
dc
pdc
mice
dc
shown
cell
popul
abl
produc
high
amount
thu
tlr
system
appear
requir
pdc
induc
antivir
respons
wherea
cdc
macrophag
fibroblast
rlr
critic
sens
ndv
recent
shown
dsrna
apoptot
bodi
virusinfect
dead
cell
recogn
dendrit
cell
dc
high
express
promot
crossprim
cell
virusinfect
cell
releas
high
amount
pbmc
caus
activ
dc
myeloid
plasmacytoid
monocyt
recent
becom
clear
import
adjuv
function
immun
respons
suggest
earli
adjuv
effect
type
ifn
could
explain
live
virus
elicit
strong
immun
respons
wherea
viral
peptid
poorli
immunogen
tolerogen
unless
supplement
exogen
adjuv
shown
induc
trail
nk
cell
monocyt
cellmedi
cytotox
interestingli
crosstalk
ifn
signal
pathway
trail
explain
fact
monocyt
ndv
upregul
express
trail
mediat
tumoricid
activ
ndv
induc
danger
signal
dc
stimul
consequ
improv
antigenpres
immun
stimulatori
function
first
publish
danger
model
immun
propos
one
mechan
immun
recognit
danger
perceiv
dc
upon
releas
cellular
content
necrosi
diseas
cell
neighborhood
recent
formul
medic
hypothesi
suggest
also
lymphocyt
correl
danger
signal
antigen
model
associ
danger
also
nonlyt
virus
upregul
danger
signal
host
cell
thu
ndv
sever
featur
enhanc
potenc
vaccin
vector
induc
immunolog
danger
signal
site
infect
contrast
virus
adapt
mammalian
immun
system
develop
viral
encod
inhibitor
immun
tap
inhibitor
cytokin
decoy
microrna
viral
protein
antagon
type
interferon
induct
ndv
induc
strong
interferon
respons
involv
earli
late
phase
earli
phase
retino
acidinduc
gene
rigi
shown
function
cdc
tumor
cell
cytoplasm
viral
rna
receptor
rigi
particip
recognit
paramyxovirus
orthomyxovirus
wherea
central
recognit
picornavirus
rigi
bind
specif
rna
contain
phosphat
viral
rna
wherea
mammalian
mrna
either
cap
contain
base
modif
may
thu
abl
discrimin
self
nonself
viral
rna
rnaactiv
bind
card
contain
adaptor
protein
signal
cascad
activ
earli
phase
interferon
regulatori
factor
irf
phosphoryl
transloc
nucleu
induc
interferon
respons
late
phase
interferon
respons
secret
interferon
molecul
interact
cell
surfaceexpress
type
ifn
receptor
initi
amplif
loop
interferon
respons
involv
stat
protein
review
see
also
found
play
import
role
gener
ctl
activ
gener
ctl
activ
mltc
assay
use
esbndv
stimul
cell
could
block
specif
antisera
type
ifn
similar
effect
observ
vivo
ctl
prime
suggest
increas
ctl
activ
essenti
gener
ctl
activ
ifn
report
induc
chain
cell
togeth
polar
cell
toward
cellmedi
helper
respons
character
delayedtyp
hypersensit
dth
cytotox
lymphocyt
ctl
activ
addit
induc
upregul
molecul
import
antigen
recognit
eg
hla
interact
eg
cell
adhes
molecul
transfect
hn
f
cdna
ndv
stimul
bhk
cell
found
lead
induct
human
blood
mononuclear
cell
ndv
excel
induc
pbmc
therebi
upregul
plasma
membran
express
trail
monocyt
cell
upon
contact
bhk
cell
express
hn
f
cell
surfac
higheffici
transfect
human
pbmc
stimul
paracrin
way
produc
stimul
human
natur
respons
pbmc
ndv
also
report
base
paramyxoviru
hemagglutinin
lectin
cell
interact
recognit
event
without
enzymat
function
like
molecular
basi
import
innat
immun
respons
envelop
viru
conclus
base
two
type
experiment
evid
strong
uv
irradi
ndv
destroy
cell
bind
hemadsorpt
neuraminidas
na
activ
hn
also
destroy
induc
activ
dna
transfect
express
hn
mutant
molecul
greatli
reduc
na
activ
induc
anoth
studi
serin
posit
hn
protein
ndv
report
import
function
activ
studi
distinct
hn
mutant
gener
sitedirect
mutagenesi
test
defin
amino
acid
respons
function
activ
hn
protein
substitut
serin
prolin
abrog
hn
express
na
activ
molecular
model
reveal
prolin
hn
influenc
flexibl
loop
near
entranc
neuraminidas
activ
site
function
may
crucial
viral
protein
paracrin
stimul
respons
human
pbmc
could
induc
either
bhk
cell
surfac
expos
viral
hn
protein
cytoplasm
viral
rna
thu
two
way
induc
innat
immun
respons
pbmc
use
two
replicon
system
base
respect
dna
rna
semliki
forest
viru
transfect
bhk
cell
produc
hnexpress
bhk
cell
bhk
cell
cytoplasm
danger
signal
dsrna
replic
intermedi
induc
compar
respons
observ
highlight
two
way
ifn
induct
addit
may
explain
high
interferogen
capac
ndv
viru
result
clarifi
molecular
mechan
involv
pattern
recognit
innat
immun
respons
role
type
interferon
induct
interferon
respons
reinforc
function
link
innat
adapt
immun
shown
fig
innat
immun
respons
provid
first
line
defens
danger
also
instruct
adapt
immun
system
mount
respons
final
proinflammatori
context
procur
addit
viru
ndv
may
interfer
induct
mechan
toler
shown
cell
clone
vitro
conclus
ndv
strong
immunostimulatori
properti
might
use
gener
strong
antitumor
immun
respons
biodistribut
oncolyt
ndv
investig
healthi
tumorbear
mice
system
iv
applic
mice
inject
intraven
hu
ndv
italien
lytic
ndv
strain
differ
organ
harvest
differ
time
point
viru
applic
rna
isol
transcrib
cdna
quantit
rtpcr
allow
determin
amount
mrna
detect
limit
copi
gene
copi
gene
viru
detect
h
iv
inject
mainli
lung
blood
liver
spleen
amount
viru
decreas
rapidli
time
reach
detect
limit
less
day
blood
thymu
day
kidney
around
day
lung
liver
spleen
ndv
wide
host
rang
least
order
bird
suscept
infect
although
wide
variat
clinic
respons
even
among
speci
genu
ndv
categor
three
pathotyp
depend
sever
diseas
caus
bird
lentogen
avirul
mesogen
intermedi
velogen
virul
lentogen
ndv
caus
overt
clinic
sign
adult
bird
consid
low
virul
virus
intermedi
virul
caus
respiratori
diseas
usual
fatal
term
mesogen
among
highli
virul
velogen
ndv
isol
viscerotrop
form
mark
lesion
digest
tract
wherea
neurotrop
form
character
clinic
respiratori
neurolog
sign
lentogen
strain
found
behav
nonlyt
viru
velogen
strain
lytic
viru
virul
ndv
strain
furin
cleavag
site
f
protein
allow
activ
proteolyt
environ
tumor
microenviron
allow
multicycl
viral
replic
crossinfect
one
tumor
cell
anoth
shown
fig
right
thu
properti
releas
progeni
viru
either
infecti
noninfecti
depend
virul
ndv
strain
cytopath
effect
lytic
ndv
strain
seen
format
plaqu
tumor
monolay
plaqu
assay
see
exampl
tissu
section
tissu
plaqu
assay
hydrophob
fusion
peptid
within
viral
envelop
promot
syncytium
format
infect
tumor
cell
wherebi
viru
spread
without
extracellular
phase
leav
oncolyt
plaqu
kill
potenti
lytic
ndv
strain
remark
strain
shown
high
capac
kill
tumor
cell
one
infecti
particl
lead
vitro
death
approxim
cancer
cell
day
extens
safeti
databas
ndv
review
see
experi
farmer
laboratori
worker
infect
ndv
show
even
wildtyp
form
produc
minim
diseas
strain
wide
evalu
treatment
human
neoplasm
repres
ulster
first
three
lytic
wherea
ulster
nonlyt
sinc
public
antineoplast
effect
ndv
ndv
test
oncolyt
agent
use
follow
differ
rout
intratumor
system
nasal
ndv
strain
inject
intratumor
dose
infecti
unit
patient
cervic
cancer
system
rout
one
develop
differ
group
differ
viru
strain
wellstat
biolog
gaithersburg
md
usa
huj
theravir
jerusalem
israel
develop
csatari
cowork
see
detail
ndv
strain
well
toler
patient
advanc
solid
cancer
dose
least
infecti
particl
iv
rout
doselimit
toxic
includ
dyspnea
diarrhea
dehydr
patient
desensit
lower
initi
dose
maximum
toler
dose
mtd
increas
tenfold
remark
system
applic
high
dose
ndv
extrem
well
toler
ndv
associ
transient
thrombocytopenia
diffus
vascular
leak
treat
patient
one
possibl
treatmentrel
death
termin
patent
report
death
associ
rapid
tumor
lysi
lung
compar
favor
safeti
problem
phase
oncolog
studi
viru
strain
attenu
variant
gener
sever
passag
chicken
embryo
origin
hertfortshir
strain
ndv
design
herz
studi
demonstr
remark
genet
stabil
even
prolong
passag
signific
number
case
primari
metastat
tumor
partial
total
regress
use
system
signific
chang
appear
also
laboratori
paramet
tumor
marker
liver
transaminas
enzym
remark
individu
case
studi
highgrad
glioma
interest
note
ndv
also
test
cancer
patient
inhal
csatari
et
al
report
seven
respons
patient
treat
twiceweekli
inhal
ndv
strain
patient
treat
hungari
inhal
howev
mani
patient
receiv
therapi
render
interpret
data
rel
efficaci
safeti
unclear
clinic
studi
come
ndv
appli
human
usual
induc
mild
fever
day
conjunct
sever
advers
effect
report
despit
applic
sever
thousand
peopl
decad
europ
usa
explain
regain
interest
ndv
anticanc
reagent
conclus
appear
ndv
advantag
vector
safeti
toler
cancer
patient
high
toler
might
relat
fact
ndv
chanc
adapt
mammalian
host
evolut
observ
combin
characterist
relat
biolog
viru
modular
natur
gene
transcript
undetect
rate
recombin
lack
dna
phase
replic
cycl
make
ndv
suitabl
candid
ration
design
safe
attenu
vaccin
gene
therapi
vector
may
addit
vivo
mechan
cell
fusion
syncytium
format
allow
viru
escap
neutral
antibodi
gener
human
popul
howev
seroneg
test
antibodi
ndv
antigen
viral
vector
abl
lead
cellular
transform
final
robust
viru
product
manufactur
system
avail
conclus
ndv
present
key
safeti
featur
develop
replicationcompet
agent
use
cancer
therapi
human
strategi
develop
tumor
vaccin
base
experi
mani
year
immunotherapi
studi
anim
tumor
model
approxim
year
ago
start
work
murin
esb
lymphoma
anim
tumor
model
esb
lymphoma
aggress
metastas
viscer
organ
particular
liver
kill
syngen
mice
within
approxim
day
oper
small
intraderm
transplant
tumor
diamet
anim
succumb
outgrowth
metastas
deriv
dissemin
tumor
cell
micrometastas
time
oper
postop
vaccin
irradi
esb
vaccin
cell
infect
uninfect
vaccin
abl
protect
approxim
mice
longterm
surviv
mice
develop
tumorspecif
protect
immun
reveal
challeng
esb
unrel
tumor
cell
effect
asi
approach
thereaft
confirm
metastas
anim
tumor
murin
melanoma
lewi
lung
carcinoma
guinea
pig
hepatocarcinoma
review
see
infect
patientderiv
tumor
cell
ndv
develop
tumor
vaccin
atvndv
larg
varieti
human
tumor
cell
shown
flow
cytometri
analysi
effici
infect
ndv
noncultur
freshli
separ
tumor
cell
use
product
atvndv
vaccin
found
infect
ndv
viral
replic
observ
independ
host
cell
prolifer
affect
viral
replic
properti
make
ndv
suitabl
agent
modif
noncultur
freshli
isol
patientderiv
tumor
cell
well
cultur
tumor
cell
line
human
tumor
cell
infect
found
effici
safe
way
produc
cancer
vaccin
pleiotrop
immun
stimulatori
properti
figur
show
diagram
recapitul
immunolog
consequ
infect
tumor
cell
ndv
elabor
atvndv
tumor
vaccin
mechan
alreadi
mention
chapter
iii
ndvinduc
cellular
chemokin
rant
apoptosi
also
enhanc
mhc
express
adhes
molecul
microenviron
antigenpres
cell
apc
cell
applic
site
vaccin
also
effect
compon
innat
system
compon
adapt
immun
system
shown
see
fig
see
review
figur
show
principl
vitro
tumor
neutral
assay
tna
repres
result
obtain
assay
virusmodifi
vaccin
pbmc
coincub
tumor
vaccin
abl
induc
variabl
degre
antitumor
activ
monolay
human
breast
carcinoma
stomach
carcinoma
cell
see
fig
c
respect
certain
number
clinic
studi
base
asi
vaccin
atvndv
perform
review
first
import
mention
intraderm
vaccin
well
toler
could
repeat
mani
time
without
caus
seriou
problem
tabl
first
studi
postop
asi
perform
cur
resect
colorect
cancer
patient
tumor
cell
vaccin
atvndv
asi
perform
phase
studi
colorect
cancer
patient
mechan
enzymat
dissoci
tumor
tissu
averag
cellsg
tissu
obtain
accord
trypan
blue
dye
exclus
assay
averag
viabil
gy
inactiv
prolif
activ
cell
could
demonstr
absenc
incorpor
tritiumlabel
thymidin
cell
still
metabol
activ
shown
uptak
tritiumlabel
uridin
mixtur
tritiumlabel
amino
acid
success
modif
tumor
cell
ulster
strain
ndv
shown
electron
microscopi
viabil
irradi
vaccin
observ
import
ctl
activ
also
clinic
efficaci
antitumor
memori
cell
cancer
patient
could
activ
frequenc
increas
antitumor
vaccin
atvndv
reveal
augment
antitumor
memori
dth
elispot
assay
dth
respons
taa
could
distinguish
respons
recal
antigen
autoimmun
respons
reactiv
ndv
alon
either
seen
weak
minor
patient
similar
distinct
respons
obtain
elispot
memori
test
vitro
base
singlecel
product
sever
cell
viru
concentr
test
patient
sixteen
patient
respond
dth
skin
reaction
vaccin
best
dth
reaction
obtain
use
vaccin
compos
tumor
cell
hu
ndv
median
indur
mm
dth
respons
vaccin
increas
throughout
repeat
vaccin
ten
patient
test
dth
respons
normal
colon
mucosa
four
respond
median
indur
mm
first
evalu
clinic
respons
reveal
follow
followup
least
month
vaccin
patient
develop
tumor
recurr
comparison
match
control
group
institut
surgic
treat
anoth
clinic
studi
patient
primari
oper
colorect
carcinoma
duke
stage
c
treat
atvndv
four
time
interv
patient
increas
reactiv
vaccin
observ
challeng
test
use
autolog
tumor
cell
without
ndv
vaccin
cycl
reveal
specif
antitumor
sensibil
patient
dth
respons
caus
bacteri
contamin
sensibl
viru
histolog
examin
vaccin
site
show
dens
infiltr
predominantli
helper
lymphocyt
conclud
patient
treat
asi
led
specif
antitumor
respons
patient
oper
local
advanc
colorect
carcinoma
receiv
asi
treat
virusinfect
atv
atvndv
treat
bacil
bcg
admix
autolog
vaccin
atvbcg
applic
atvndv
vaccin
associ
mild
side
effect
wherea
atvbcg
vaccin
led
longlast
ulcer
seriou
side
effect
surviv
rate
atvndv
wherea
surviv
rate
atvbcg
mean
surviv
patient
histor
control
see
tabl
data
suggest
type
qualiti
tumor
vaccin
asi
treatment
import
anoth
clinic
studi
perform
patient
advanc
renal
cell
carcinoma
treat
sequenti
autolog
tumor
vaccin
atvndv
subcutan
administr
thirti
patient
advanc
renal
cell
carcinoma
rcc
enter
nephrectomi
protocol
three
patient
exhibit
complet
respons
four
display
partial
remiss
seven
show
stabl
diseas
month
median
month
progress
seen
nine
conclud
vaccin
combin
cytokin
induc
regress
patient
advanc
rcc
even
nonrespond
patient
favor
cours
diseas
achiev
longer
followup
report
tumor
respons
surviv
data
patient
advanc
renal
carcinoma
treat
autolog
tumor
vaccin
subcutan
recombin
evalu
rcc
patient
exhibit
complet
respons
cr
display
partial
remiss
pr
show
stabl
diseas
sd
median
surviv
month
tumor
progress
twentythre
patient
either
cr
pr
sd
appear
signific
surviv
advantag
compar
patient
progress
diseas
treatment
period
compar
histor
refer
group
qualiti
efficaci
criteria
evalu
atvndv
vaccin
analyz
three
independ
cohort
b
c
breast
ovarian
cancer
patient
vaccin
cohort
includ
patient
primari
breast
cancer
cohort
b
includ
patient
metastat
pretreat
breast
cancer
cohort
c
includ
patient
metastat
pretreat
ovarian
cancer
retrospect
hypothes
immunogen
vaccin
contain
least
viabl
tumor
cell
viabil
least
cohort
thu
divid
two
group
one
receiv
vaccin
type
fulfil
criteria
type
b
miss
one
criteria
prognost
factor
well
balanc
b
cohort
c
cohort
benefit
surviv
p
type
rel
risk
die
group
receiv
type
compar
type
b
univari
cox
model
cohort
c
like
cohort
surviv
benefit
vaccin
type
may
ascrib
vaccin
qualiti
prognost
factor
bias
could
impli
clinic
effect
breast
ovarian
cancer
atvndv
highqual
vaccin
outcom
clinic
trial
antitumor
vaccin
atvndv
review
review
includ
followup
evalu
earlier
publish
phase
ii
studi
tabl
summar
respect
surviv
rate
obtain
studi
asi
studi
local
advanc
primari
breast
cancer
followup
reveal
surviv
rate
higher
group
highqual
vaccin
group
b
lowqual
vaccin
colorect
carcinoma
studi
increas
surviv
rate
group
patient
receiv
highqual
atvndv
vaccin
see
tabl
studi
led
follow
conclus
postop
vaccin
atvndv
deriv
fresh
oper
specimen
appear
feasibl
safe
colorect
carcinoma
breast
ovarian
cancer
advanc
renal
cell
carcinomatumor
cell
number
cell
viabil
appear
import
vaccin
qualityappl
highqual
atvndv
vaccin
appear
improv
prognosi
surviv
vaccin
patient
anoth
clinic
studi
antitumor
vaccin
perform
patient
suffer
glioblastoma
multiform
pilot
studi
assess
feasibl
safeti
clinic
benefit
nonrandom
studi
patient
vaccin
postop
result
compar
nonvaccin
control
subject
n
vaccin
prepar
patient
tumor
cell
cultur
infect
ndv
follow
appli
eight
time
establish
tumor
cell
cultur
success
approxim
patient
vaccin
sever
side
effect
observ
median
progressionfre
surviv
vaccin
patient
week
versu
week
control
subject
p
median
overal
surviv
vaccin
patient
week
versu
week
control
subject
p
vaccin
group
immun
monitor
reveal
signific
increas
dth
reactiv
number
tumorreact
memori
cell
number
tumorinfiltr
lymphocyt
secondari
tumor
also
perform
antitumor
vaccin
patient
head
neck
squamou
cell
carcinoma
hnscc
nonrandom
pilot
studi
patient
vaccin
postop
atvndv
establish
patientderiv
tumor
cell
cultur
success
approxim
case
vaccin
sever
side
effect
observ
percentag
surviv
vaccin
patient
stage
iii
stage
iv
tumor
n
year
see
tabl
immun
monitor
reveal
signific
increas
antitumor
dth
reactiv
signific
proport
vaccin
patient
presenc
tumorreact
cell
peripher
blood
even
year
last
vaccin
postop
vaccin
atvndv
may
improv
prognosi
hnscc
patient
advanc
tumor
conclus
clinic
studi
perform
demonstr
postop
vaccin
atvndv
deriv
cell
cultur
feasibl
safe
although
obtain
random
studi
show
strong
tendenc
improv
surviv
upon
vaccin
atvndv
could
substanti
observ
vaccinationinduc
improv
antitumor
immun
respons
posit
correl
increas
dth
respons
atvndv
prognosi
observ
clinic
data
present
summar
tabl
tabl
list
possibl
explan
result
vaccin
strategi
aim
develop
cell
costimulatori
molecul
broadli
applic
augment
antitumor
immun
respons
upon
applic
atvndv
tumor
vaccin
cancer
patient
end
gener
recombin
bispecif
singlechain
antibodi
dual
bind
specif
one
direct
toward
antigen
express
human
cell
one
specif
viral
target
molecul
hn
express
surfac
atvndv
bispecif
molecul
name
respect
redirect
unstimul
human
cell
hnexpress
ndvinfect
tumor
cell
bispecif
molecul
found
crosslink
effector
target
cell
rapidli
induc
cytotox
nanomolar
concentr
figur
show
scheme
new
immunostimulatori
fusion
protein
way
function
combin
vaccin
atvndv
protein
enhanc
signal
molecul
exert
cell
costimulatori
function
led
increas
signal
maxim
cell
activ
achiev
tumor
cell
infect
ndv
modifi
new
stimulatori
molecul
time
reveal
cell
prolifer
upregul
releas
cytokin
interferon
chemokin
conclud
newli
develop
molecul
combin
high
effici
specif
safeti
also
observ
bound
via
one
arm
human
tumorndv
vaccin
new
molecul
caus
polyclon
cell
respons
could
overcom
potenti
variou
cell
evas
mechan
tumor
cell
tna
assay
present
fig
pbmc
purifi
cell
activ
breast
stomach
carcinoma
vaccin
infect
ndv
modifi
abl
destroy
complet
monolay
carcinoma
cell
see
fig
nontumor
target
cell
appear
much
less
sensit
activ
effector
cell
new
bioactiv
molecul
combin
establish
tumor
augment
antitumor
activ
cell
healthi
donor
cancer
patient
secondgener
vaccin
far
superior
firstgener
vaccin
atvndv
immunogen
activ
cell
less
depend
taa
recognit
consequ
also
expect
less
affect
tumor
immun
escap
mechan
also
develop
novel
strategi
target
recombin
ndv
tumor
cell
gene
therapi
purpos
modifi
bind
properti
viru
attach
adaptor
molecul
neutral
viru
restor
bind
properti
viral
particl
proof
principl
construct
use
recombin
molecul
contain
scfv
antibodi
clone
neutral
hnspecif
hybridoma
link
human
cytokin
observ
modifi
viru
bispecif
fusion
protein
allow
viru
receptorindepend
tumor
cell
bind
gene
transfer
hemadsorpt
neuraminidas
na
activ
hn
ndv
shown
block
recombin
ndv
express
enhanc
green
fluoresc
protein
egfp
appli
show
express
foreign
gene
viru
infect
tumor
cell
select
viru
entri
receptorbear
tumor
cell
observ
mixtur
jurkat
receptor
posit
tumor
cell
retarget
viru
bind
tumor
cell
suffici
process
viru
infect
requir
addit
membran
fusion
via
viral
f
protein
purpos
anoth
studi
investig
specif
effici
gene
deliveri
tumor
cell
vivo
via
modifi
ndv
viru
h
intratumor
deliveri
direct
fluoresc
microscopi
immunohistolog
reveal
viral
replic
targetposit
tumor
tissu
result
much
egfp
express
targetneg
tumor
tissu
biodistribut
studi
show
egfp
transgen
deliveri
reduc
liver
spleen
kidney
lung
thymu
wherea
transgen
deliv
tumor
tumor
therapi
experi
reveal
side
effect
liver
kidney
induc
system
viru
applic
greatli
reduc
adaptor
protein
wherea
antitumor
effect
mostli
undiminish
conclus
modif
recombin
ndv
bispecif
molecul
appear
novel
safe
strategi
select
gene
transfer
target
tumor
cell
demonstr
signific
system
antitumor
activ
retarget
viral
vector
suggest
potenti
improv
inclus
one
therapeut
gene
use
recombin
dna
technolog
possibl
gener
recombin
strain
nonseg
negativestrand
rna
virus
revers
genet
system
establish
differ
laboratori
recov
recombin
ndv
recndv
entir
clone
cdna
uniqu
molecular
genet
methodolog
provid
mean
investig
function
variou
virusencod
gene
detail
lead
extraordinari
advanc
understand
biolog
exampl
gener
recndv
reduc
v
protein
express
lack
pathogen
chicken
embryo
show
import
v
protein
viral
pathogen
chicken
addit
develop
virus
allow
use
virus
express
heterolog
foreign
gene
way
ndv
could
specif
design
efficaci
enhanc
describ
recent
oncolyt
vaccin
purpos
certain
characterist
ndv
suggest
recndv
express
foreign
protein
would
good
vaccin
candid
deliv
protect
antigen
respiratori
diseas
pathogen
ndv
natur
infect
via
respiratori
alimentari
tract
mucos
surfac
gene
encod
foreign
protein
insert
ndv
genom
express
togeth
ndv
protein
contrast
pox
herp
viru
vector
express
larg
number
addit
protein
larg
genom
recent
studi
gene
encod
granulocytemacrophag
colonystimul
factor
gmcsf
insert
addit
transcript
unit
two
differ
posit
ndv
genom
recndv
strongest
product
gene
product
correspond
insert
gmcsf
gene
np
gene
select
studi
see
fig
observ
concord
previou
data
show
effect
genom
locat
insert
foreign
gene
gene
express
gene
product
biolog
activ
stabl
tumor
vaccin
cell
infect
recndv
gmcsf
incorpor
gene
rec
gmcsf
stimul
human
pbmc
exert
antitumor
bystand
effect
vitro
tumor
neutral
assay
tna
describ
fig
effect
significantli
increas
compar
vaccin
infect
recndv
without
insert
gene
rec
finer
analysi
show
rec
gmcsf
led
much
higher
respons
rec
ad
viru
virusmodifi
vaccin
pbmc
furthermor
two
distinct
cell
type
plasmacytoid
dc
pdc
monocyt
shown
contribut
augment
respons
pbmc
conclud
alreadi
inher
antineoplast
immunostimulatori
properti
ndv
could
augment
introduct
therapeut
gene
proof
principl
observ
also
gmcsf
initi
combin
viru
broad
cascad
immunolog
effect
microenviron
tumor
vaccin
fig
recent
studi
confirm
potenti
recombin
ndv
vaccin
vector
express
level
foreign
protein
eg
chloramphenicol
acetyltransferas
cat
influenza
viru
hemagglutinin
high
foreign
gene
stabl
mani
passag
vitro
vivo
recndv
modifi
insert
gene
cassett
encod
human
parainfluenza
viru
type
hn
protein
p
gene
shown
induc
high
serum
antibodi
respons
foreign
hn
protein
induc
first
immun
although
somewhat
less
observ
wildtyp
infect
howev
titer
second
immun
exceed
titer
observ
infect
even
though
replic
much
effici
ndv
anim
furthermor
recndv
complet
protect
chicken
mice
lethal
challeng
homolog
heterolog
avian
influenza
virus
recombin
newcastl
diseas
viru
ndv
capsid
display
enteroviru
fragment
shown
also
abl
induc
strong
immun
respons
rabbit
ndv
express
hemagglutinin
gene
protect
chicken
newcastl
diseas
also
avian
influenza
recndv
express
protein
infecti
bursal
diseas
viru
ibdv
also
shown
protect
ndv
ibdv
similar
result
obtain
recombin
ndv
engin
express
sarscov
spike
glycoprotein
protect
african
green
monkey
challeng
high
dose
sarscov
viru
therefor
suggest
ndv
might
perfect
vector
intranas
immun
newli
emerg
pathogen
technolog
revers
genet
use
modifi
bind
properti
ndv
done
measl
viru
condit
replic
exampl
virologist
region
colleg
veterinari
medicin
virginia
tech
look
genet
modifi
variant
ndv
use
treat
human
prostat
cancer
dr
elankurmaran
subbiah
cowork
alter
fusion
protein
ndv
replic
presenc
prostat
specif
antigen
psa
publish
also
possibl
engin
recndv
allow
retarget
tumor
clone
fragment
antibodi
viral
f
hn
protein
recndv
may
also
engin
secret
full
intact
antibodi
respect
heavi
light
chain
igg
hybridoma
incorpor
viral
genom
recndv
tumorselect
bind
properti
secret
antibodi
would
allow
high
antibodi
concentr
tumor
microenviron
reach
allow
deeper
penetr
antibodi
tissu
solid
tumor
could
avoid
side
effect
observ
system
applic
antibodi
insert
gene
ndv
drug
activ
could
benefit
associ
applic
anticanc
drug
envelop
negativestrand
rna
virus
packag
constraint
encapsul
dna
virus
nevertheless
remain
determin
mani
transgen
may
express
maxim
genom
size
may
toler
ndv
conclus
ndv
appear
attract
vector
viru
therapi
immun
therapi
also
gene
therapi
cancer
